IL6 and COVID-19: Apart from IL-6, the trend of other cytokines whose targeting is already available in the clinic does not appear uniform in COVID-19 (30, 41, 54, 63), hampering the possibility of tailored treatments and contrasting with the apparent efficacy of some agents, such as IL-1 antagonists, in preliminary observational studies (21, 22).